• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Cancer growth"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 29

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience 

      Pectasides, Dimitrios; Fountzilas, George; Aravantinos, Gerasimos; Kalofonos, H. P.; Efstathiou, E.; Farmakis, D.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Economopoulos, T.; Dimopoulos, M. A. (2006)
      Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...

    • Article  

      Cancer of unknown primary site: 20 questions to be answered 

      Pavlidis, Nicholas; Pentheroudakis, George (2010)
      Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

    • Article  

      CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group 

      Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)
      Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

    • Article  

      Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? 

      Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Fountzilas, George; Xeros, N.; Samelis, G.; Samantas, E.; Pavlidis, Nicholas (2005)
      Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...

    • Article  

      Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components 

      Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Charchanti, A.; Damala, K.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)
      Syndecan-1, a cell surface proteoglycan found predominantly on epithelia of mature tissues, binds both extracellular matrix (ECM) components and basic fibroblast growth factor (bFGF) and is implicated in the restriction ...

    • Article  

      Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group 

      Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)
      To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...

    • Article  

      Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study 

      Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)
      Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

    • Article  

      Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group 

      Skarlos, Dimosthenis V.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Papakostas, P.; Pavlidis, Nicholas; Bacoyiannis, Charalambos; Kiamouris, Ch; Klouvas, G. D.; Gogas, H.; Fountzilas, George; Samantas, E. (2003)
      There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part ...

    • Article  

      Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study 

      Fountzilas, George; Nikolaides, C.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Samelis, G.; Aravantinos, Gerasimos; Pavlidis, Nicholas (2000)
      A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a ...

    • Article  

      Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG) 

      Pectasides, Dimitrios; Papaxoinis, G.; Fountzilas, George; Aravantinos, Gerasimos; Bamias, A. T.; Pavlidis, Nicholas; Kalofonos, H. P.; Timotheadou, E.; Samantas, E.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Economopoulos, T.; Dimopoulos, M. A. (2009)
      Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...

    • Article  

      Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group 

      Nikolaides, C.; Dimopoulos, M. A.; Samantas, E.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Fountzilas, George; Razi, E. D.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)
      Background: Gemcitabine and vinorelbine have shown activity in breast cancer. A phase II trial was initiated in order to evaluate the response rate (RR) and time to progression (TTP) of the combination of the two drugs in ...

    • Article  

      Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group 

      Briassoulis, E. Ch; Pavlidis, Nicholas; Terret, C.; Bauer, J.; Fiedler, W.; Schöffski, P.; Raoul, J. L.; Hess, D.; Selvais, R.; Lacombe, D.; Bachmann, P.; Fumoleau, P. (2003)
      The activity of glufosfamide (β-D-glucopyranosyl-N,N′ -di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naïve patients with ...

    • Article  

      Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer 

      Aravantinos, Gerasimos; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kiamouris, Ch; Pavlidis, Nicholas; Sikiotis, K.; Papakostas, P.; Skarlos, Dimosthenis V. (2000)
      Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide ...

    • Article  

      Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression 

      Ioachim, E.; Charchanti, A.; Briassoulis, E. Ch; Karavasilis, V.; Tsanou, E.; Arvanitis, D. L.; Agnantis, Niki J.; Pavlidis, Nicholas (2002)
      The immunohistochemical expression of the extracellular matrix (ECM) components tenascin (TN), fibronectin (FN), collagen type IV (Coll) and laminin (LN), and their possible relationships were studied in a series of 134 ...

    • Article  

      Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation 

      Mauri, D.; Pentheroudakis, George; Ch, F. Tolis; Chojnacka, M.; Pavlidis, Nicholas (2005)
      Purpose: To identify the incidence of prostate cancer associated-systemic inflammatory syndrome (SIS), and to characterize further this entity, we searched our database as well as the medical literature. Methods: We ...

    • Article  

      Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation 

      Minas, V.; Rolaki, A.; Kalantaridou, S. N.; Sidiropoulos, J.; Mitrou, Sotirios; Petsas, G.; Jeschke, U.; Paraskevaidis, E.; Fountzilas, George; Chrousos, George P.; Pavlidis, Nicholas; Makrigiannakis, A. (2007)
      Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established. FasL plays an important ...

    • Article  

      Lung cancer in pregnancy: Report of nine cases from an international collaborative study 

      Boussios, Stergios; Han, S. N.; Fruscio, R.; Halaska, M. J.; Ottevanger, P. B.; Peccatori, Fedro A.; Koubková, L.; Pavlidis, Nicholas; Amant, F. (2013)
      Objective: Lung cancer is an uncommon diagnosis during pregnancy. The combination of smoking in young women, increased maternal age during pregnancy, and increasing incidence of lung cancer worldwide may cause an increase ...

    • Article  

      Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study 

      Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)
      Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...

    • Article  

      Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group 

      Fountzilas, George; Pectasides, Dimitrios; Kalogera-Fountzila, Anna; Skarlos, Dimosthenis V.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, Dimitrios; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briassoulis, E. Ch; Pavlidis, Nicholas; Razi, E. D.; Kosmidis, Paraskevas A.; Gogas, H. (2005)
      Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...

    • Article  

      Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: A hellenic cooperative oncology group phase II study 

      Fountzilas, George; Ch, F. Tolis; Kalogera-Fountzila, Anna; Misailidou, D.; Tsekeris, P.; Karina, M.; Nikolaou, A.; Samantas, E.; Makatsoris, T.; Athanassiou, E.; Skarlos, Dimosthenis V.; Bamias, A. T.; Zamboglou, N.; Economopoulos, T.; Karanastassi, S.; Pavlidis, Nicholas; Daniilidis, J. (2005)
      The primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD